Sort   by:  
 Page size 
TranscriptomicsGenomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients...
ORGANISM(S): Homo sapiens 
2019-09-21 | E-MTAB-8340 | biostudies-arrayexpress
ProteomicsVestibular schwannoma is comprised of neural crest and immune subgroups
Vestibular schwannomas (VS) are tumors arising from cranial nerve Schwann cells that cause significant morbidity and are treated with surgery and irradiation. We describe a DNA methylation-based classification of VS into neural crest and immune enriched subgroups and validate our findings using bulk...
ORGANISM(S): Homo Sapiens 
PXD014883 | panorama
UnknownNational-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
Not available
S-EPMC11694015 | biostudies-literature
UnknownGlobal, regional, and national burden of suicide, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Not available
S-EPMC11876099 | biostudies-literature
UnknownGlobal, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021.
Not available
S-EPMC12557468 | biostudies-literature
UnknownBurden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.
Not available
S-EPMC11715278 | biostudies-literature
UnknownValidation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery.
Not available
S-EPMC8855527 | biostudies-literature
UnknownAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Not available
S-EPMC3235950 | biostudies-literature
UnknownBurden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.
Not available
S-EPMC11121021 | biostudies-literature
UnknownForecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
Not available
S-EPMC11447278 | biostudies-literature
Sort   by:  
 Page size